Serotype Distrubution and Antibiotic Susceptibilities of Streptococcus pneumoniae Causing Acute Exacerbations and Pneumonia in Children with Chronic Respiratory Diseases
0301 basic medicine
0303 health sciences
Adolescent
Genotype
Respiratory Tract Diseases
Infant
Pneumonia, Pneumococcal
Pneumococcal Infections
Anti-Bacterial Agents
3. Good health
Pneumococcal Vaccines
03 medical and health sciences
Phenotype
Streptococcus pneumoniae
Disk Diffusion Antimicrobial Tests
Child, Preschool
Acute Disease
Chronic Disease
Drug Resistance, Bacterial
Humans
Macrolides
Serotyping
Child
Multiplex Polymerase Chain Reaction
DOI:
10.5578/mb.5655
Publication Date:
2013-11-20T14:46:15Z
AUTHORS (7)
ABSTRACT
This study aimed to investigate serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates obtained from children with chronic respiratory diseases admitted hospital a diagnosis acute exacerbations between 2008-2010 at Marmara University Hospital, Istanbul, Turkey. Sixty one S.pneumoniae strains isolated the samples patients were studied for erythromycin, clindamycin, tetracyline, trimethoprim-sulphametoxazole (TMP-SMX), vancomycin, levofloxacin susceptibilities by disk diffusion method; MIC values penicillin ceftriaxone determined E-test (AB Biodisk, Sweden). Results evaluated according CLSI standards. The erythromycin-clindamycin double disc method was applied detection macrolide phenotypes. presence genes, ermB, mef(A)/(E), ermTR PCR using specific primers each gene. serotypes multiplex 40 different serotypes. According criteria, in found be 8.2% (5/61) intermediate rate 54% (33/61) oral penicillin. Penicillin only 1.6% (1/61) parenteral Resistance rates TMP-SMX detected as 55.8%, 46%, 47.5% 67.2%; respectively. No vancomycin levofloxacin. Constitutive macrolide-lincosamide-streptogramin B (cMLSB) phenotype M observed 82.4% (n= 28) 17.6% 6) resistant isolates, Inducible (iMLSB) not detected. macrolid genotypes, positive 50% 14.7%; Both ermB mef(A)/(E) genes 35.3% isolates. None most common 19F, 23F 6, furthermore (34%, 15.7% 18.4%, respectively) (38.2%, 20.6% 14.7%, those relatively high. Serotype covarage 7-, 10-, 13-valent conjugated pneumococcal vaccines 23-valent vaccine 65%, 67%, 69%, 78.6%, In our country, use these coverage has been effective exposed intensive antibiotics lung disease.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (1)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....